Literature DB >> 26019347

Mutant alpha-synuclein causes age-dependent neuropathology in monkey brain.

Weili Yang1, Guohao Wang2, Chuan-En Wang3, Xiangyu Guo1, Peng Yin1, Jinquan Gao1, Zhuchi Tu1, Zhengbo Wang4, Jing Wu4, Xintian Hu4, Shihua Li3, Xiao-Jiang Li5.   

Abstract

Parkinson's disease (PD) is an age-dependent neurodegenerative disease that often occurs in those over age 60. Although rodents and small animals have been used widely to model PD and investigate its pathology, their short life span makes it difficult to assess the aging-related pathology that is likely to occur in PD patient brains. Here, we used brain tissues from rhesus monkeys at 2-3, 7-8, and >15 years of age to examine the expression of Parkin, PINK1, and α-synuclein, which are known to cause PD via loss- or gain-of-function mechanisms. We found that α-synuclein is increased in the older monkey brains, whereas Parkin and PINK1 are decreased or remain unchanged. Because of the gain of toxicity of α-synuclein, we performed stereotaxic injection of lentiviral vectors expressing mutant α-synuclein (A53T) into the substantia nigra of monkeys and found that aging also increases the accumulation of A53T in neurites and its associated neuropathology. A53T also causes more extensive reactive astrocytes and axonal degeneration in monkey brain than in mouse brain. Using monkey brain tissues, we found that A53T interacts with neurofascin, an adhesion molecule involved in axon subcellular targeting and neurite outgrowth. Aged monkey brain tissues show an increased interaction of neurofascin with A53T. Overexpression of A53T causes neuritic toxicity in cultured neuronal cells, which can be attenuated by transfected neurofascin. These findings from nonhuman primate brains reveal age-dependent pathological and molecular changes that could contribute to the age-dependent neuropathology in PD.
Copyright © 2015 the authors 0270-6474/15/358345-14$15.00/0.

Entities:  

Keywords:  Parkinson's; aging; degeneration; neurite; primate

Mesh:

Substances:

Year:  2015        PMID: 26019347      PMCID: PMC4444551          DOI: 10.1523/JNEUROSCI.0772-15.2015

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  43 in total

Review 1.  Alpha-synuclein and neurodegenerative diseases.

Authors:  M Goedert
Journal:  Nat Rev Neurosci       Date:  2001-07       Impact factor: 34.870

2.  Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death.

Authors:  L Stefanis; K E Larsen; H J Rideout; D Sulzer; L A Greene
Journal:  J Neurosci       Date:  2001-12-15       Impact factor: 6.167

3.  Aged monkey brains reveal the role of ubiquitin-conjugating enzyme UBE2N in the synaptosomal accumulation of mutant huntingtin.

Authors:  Peng Yin; Zhuchi Tu; An Yin; Ting Zhao; Sen Yan; Xiangyu Guo; Renbao Chang; Lianhe Zhang; Yan Hong; Xiahe Huang; Junxia Zhou; Yingchun Wang; Shihua Li; Xiao-Jiang Li
Journal:  Hum Mol Genet       Date:  2014-10-24       Impact factor: 6.150

4.  Early Parkinson's disease symptoms in α-synuclein transgenic monkeys.

Authors:  Yuyu Niu; Xiangyu Guo; Yongchang Chen; Chuan-En Wang; Jinquan Gao; Weili Yang; Yu Kang; Wei Si; Hong Wang; Shang-Hsun Yang; Shihua Li; Weizhi Ji; Xiao-Jiang Li
Journal:  Hum Mol Genet       Date:  2014-12-30       Impact factor: 6.150

5.  Evaluating dot and Western blots using image analysis and pixel quantification of electronic images.

Authors:  J L Vierck; K M Bryne; M V Dodson
Journal:  Methods Cell Sci       Date:  2000

6.  α-Synuclein protects against manganese neurotoxic insult during the early stages of exposure in a dopaminergic cell model of Parkinson's disease.

Authors:  Dilshan S Harischandra; Huajun Jin; Vellareddy Anantharam; Arthi Kanthasamy; Anumantha G Kanthasamy
Journal:  Toxicol Sci       Date:  2014-11-21       Impact factor: 4.849

7.  alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.

Authors:  C Lo Bianco; J-L Ridet; B L Schneider; N Deglon; P Aebischer
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-16       Impact factor: 11.205

8.  Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein.

Authors:  Benoit I Giasson; John E Duda; Shawn M Quinn; Bin Zhang; John Q Trojanowski; Virginia M-Y Lee
Journal:  Neuron       Date:  2002-05-16       Impact factor: 17.173

9.  SnapShot: Genetics of Parkinson's disease.

Authors:  José Brás; Rita Guerreiro; John Hardy
Journal:  Cell       Date:  2015-01-29       Impact factor: 41.582

Review 10.  Glia and alpha-synuclein in neurodegeneration: A complex interaction.

Authors:  Dominik Brück; Gregor K Wenning; Nadia Stefanova; Lisa Fellner
Journal:  Neurobiol Dis       Date:  2015-03-10       Impact factor: 5.996

View more
  29 in total

1.  Paroxetine suppresses reactive microglia-mediated but not lipopolysaccharide-induced inflammatory responses in primary astrocytes.

Authors:  Xiong Zhang; Lan-Bing Zhu; Jia-Hui He; Hong-Qiu Zhang; Shu-Ya Ji; Chao-Nan Zhang; Na-Na Hou; Chen-Ping Huang; Jian-Hong Zhu
Journal:  J Neuroinflammation       Date:  2020-02-05       Impact factor: 8.322

2.  Mutant Huntingtin Impairs BDNF Release from Astrocytes by Disrupting Conversion of Rab3a-GTP into Rab3a-GDP.

Authors:  Yan Hong; Ting Zhao; Xiao-Jiang Li; Shihua Li
Journal:  J Neurosci       Date:  2016-08-24       Impact factor: 6.167

3.  Chronic and age-dependent effects of the spongiform neurodegeneration-associated MGRN1 E3 ubiquitin ligase on mitochondrial homeostasis.

Authors:  Teresa M Gunn; Derek Silvius; Andrew Lester; Britney Gibbs
Journal:  Mamm Genome       Date:  2019-05-14       Impact factor: 2.957

Review 4.  Animal models of α-synucleinopathy for Parkinson disease drug development.

Authors:  James B Koprich; Lorraine V Kalia; Jonathan M Brotchie
Journal:  Nat Rev Neurosci       Date:  2017-07-13       Impact factor: 34.870

Review 5.  The use of nonhuman primate models to understand processes in Parkinson's disease.

Authors:  Javier Blesa; Inés Trigo-Damas; Natalia López-González Del Rey; José A Obeso
Journal:  J Neural Transm (Vienna)       Date:  2017-03-29       Impact factor: 3.575

Review 6.  Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.

Authors:  Gunasingh J Masilamoni; Yoland Smith
Journal:  J Neural Transm (Vienna)       Date:  2017-08-31       Impact factor: 3.575

Review 7.  α-Synuclein nonhuman primate models of Parkinson's disease.

Authors:  David J Marmion; Jeffrey H Kordower
Journal:  J Neural Transm (Vienna)       Date:  2017-04-22       Impact factor: 3.575

Review 8.  α-Synuclein and nonhuman primate models of Parkinson's disease.

Authors:  Scott C Vermilyea; Marina E Emborg
Journal:  J Neurosci Methods       Date:  2015-08-03       Impact factor: 2.390

9.  Natural product HTP screening for attenuation of cytokine-induced neutrophil chemo attractants (CINCs) and NO2- in LPS/IFNγ activated glioma cells.

Authors:  Elizabeth A Mazzio; David Bauer; Patricia Mendonca; Equar Taka; Karam F A Soliman
Journal:  J Neuroimmunol       Date:  2016-12-01       Impact factor: 3.478

10.  Nonhuman Primate Models of Neurodegenerative Disorders.

Authors:  Marina E Emborg
Journal:  ILAR J       Date:  2017-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.